Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses
J Am Soc Nephrol. 2024 Sep 4.
doi: 10.1681/ASN.0000000000000491.
Online ahead of print.
1 Department of Medicine, Baylor University Medical Center, Dallas, Texas.
2 Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
3 Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
4 Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore.
5 Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, Massachusetts.
6 Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
7 Division of Nephrology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada.
8 Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
9 Division of Nephrology, Washington DV VA Medical Center, Washington, DC.
10 Department of Cardiology, Smidt Heart Institute, Los Angeles, California.
11 Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
12 Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
13 Renal Research Unit, Comprehensive Heart Failure Center, Department of Clinical Research and Epidemiology, University of Würzburg, Würzburg, Germany.
14 Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
15 Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
16 Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, Texas.